<DOC>
	<DOCNO>NCT02439008</DOCNO>
	<brief_summary>This study follow-up immune cell population , secrete factor release nanovesicles blood , high dose radiation therapy give new information efficacy hypofractionated high dose radiation therapy rationale adjuvant immunotherapy .</brief_summary>
	<brief_title>Early Biomarkers Tumor Response High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response</brief_title>
	<detailed_description>- Patient information collection sign informed consent form - Clinical data collection - Blood sample 35 mL : 1. registration , prior first fraction radiotherapy 2. within 15 minute administration 1st , 2nd 3rd radiotherapy session 3. one week , 3 month , 6 month , 9 month 12 month last radiotherapy session - Storage blood sample ambient temperature - Transportation sample Institute Biology Lille ( IBL ) - CNRS UMR8161 analysis - Destruction sample end analysis</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>Patient require hypofractionated irradiation ( ≥ 3 fraction , dose ≥ 9 Gy per fraction ) either : hepatocellular carcinoma hepatic lesion metastatic Colorectal Cancer , metastasis melanoma renal cancer , Age ≥ 18 year old , Registered social security system , Signed write informed consent . Patient treat chemotherapy , target immunotherapy within 21 day first sample , Pregnant breastfeed woman , Patient guardianship tutorship .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>liver metastasis colorectal cancer</keyword>
	<keyword>metastasis melanoma renal cancer</keyword>
</DOC>